BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moctezuma-Velazquez C, Kalainy S, Abraldes JG. Beta-blockers in patients with advanced liver disease: Has the dust settled? Liver Transpl. 2017;23:1058-1069. [PMID: 28590564 DOI: 10.1002/lt.24794] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Kumar P, Taneja S, Singh V. Beta-blockers in patients with advanced liver disease: Has the dust settled? Liver Transpl 2017;23:1351-2. [PMID: 28752927 DOI: 10.1002/lt.24831] [Reference Citation Analysis]
2 Alvarado-Tapias E, Ardevol A, Garcia-Guix M, Montañés R, Pavel O, Cuyas B, Graupera I, Brujats A, Vilades D, Colomo A, Poca M, Torras X, Guarner C, Concepción M, Aracil C, Torres F, Villanueva C. Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis. J Hepatol 2020;73:829-41. [PMID: 32298768 DOI: 10.1016/j.jhep.2020.03.048] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
3 Kockerling D, Nathwani R, Forlano R, Manousou P, Mullish BH, Dhar A. Current and future pharmacological therapies for managing cirrhosis and its complications. World J Gastroenterol 2019; 25(8): 888-908 [PMID: 30833797 DOI: 10.3748/wjg.v25.i8.888] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
4 Kalambokis GN, Christaki M, Tsiakas I, Despotis G, Fillipas-Ntekouan S, Fotopoulos A, Tsiouris S, Xourgia X, Lakkas L, Pappas K, Michalis LK, Sergianiti F, Baltayiannis G, Christodoulou D, Koustousi C, Aggelis N, Milionis H. Conversion of Propranolol to Carvedilol Improves Renal Perfusion and Outcome in Patients With Cirrhosis and Ascites. J Clin Gastroenterol 2021;55:721-9. [PMID: 32991355 DOI: 10.1097/MCG.0000000000001431] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Fukui H, Kawaratani H, Kaji K, Takaya H, Yoshiji H. Management of refractory cirrhotic ascites: challenges and solutions. Hepat Med. 2018;10:55-71. [PMID: 30013405 DOI: 10.2147/hmer.s136578] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Yoon KT, Liu H, Lee SS. β-blockers in advanced cirrhosis: More friend than enemy. Clin Mol Hepatol 2021;27:425-36. [PMID: 33317244 DOI: 10.3350/cmh.2020.0234] [Reference Citation Analysis]
7 Moctezuma-velazquez C, Kalainy S, Abraldes JG. Reply: Moctezuma-Velazquez et al. Liver Transpl 2017;23:1353-1353. [DOI: 10.1002/lt.24834] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations. JHEP Rep 2020;2:100063. [PMID: 32039404 DOI: 10.1016/j.jhepr.2019.12.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
9 Wang J, Wu Y, Bi Q, Zheng X, Zhang J, Huang W. Adverse outcomes of proton pump inhibitors in chronic liver disease: a systematic review and meta-analysis. Hepatol Int 2020;14:385-98. [PMID: 31912308 DOI: 10.1007/s12072-019-10010-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
10 Kovacs TOG, Jensen DM. Varices: Esophageal, Gastric, and Rectal. Clin Liver Dis. 2019;23:625-642. [PMID: 31563215 DOI: 10.1016/j.cld.2019.07.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
11 Giannini EG, Giambruno E, Brunacci M, Plaz Torres MC, Furnari M, Bodini G, Zentilin P, Savarino V. Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients. Ann Hepatol 2018;17:830-5. [PMID: 30145561 DOI: 10.5604/01.3001.0012.0775] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
12 Ngwa T, Orman E, Gomez EV, Vuppalanchi R, Kubal C, Chalasani N, Ghabril M. Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation. BMC Gastroenterol 2020;20:4. [PMID: 31906860 DOI: 10.1186/s12876-019-1155-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
13 Kreisel W, Schaffner D, Lazaro A, Trebicka J, Merfort I, Schmitt-Graeff A, Deibert P. Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. Int J Mol Sci 2020;21:E6223. [PMID: 32872119 DOI: 10.3390/ijms21176223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
14 Veldhuijzen van Zanten D, Buganza E, Abraldes JG. The Role of Hepatic Venous Pressure Gradient in the Management of Cirrhosis. Clin Liver Dis 2021;25:327-43. [PMID: 33838853 DOI: 10.1016/j.cld.2021.01.002] [Reference Citation Analysis]
15 Maiwall R, Pasupuleti SSR, Jain P, Sarin SK. Degree of Portal and Systemic Hemodynamic Alterations Predict Recurrent AKI and Chronic Kidney Disease in Patients With Cirrhosis. Hepatol Commun 2021;5:293-308. [PMID: 33553976 DOI: 10.1002/hep4.1607] [Reference Citation Analysis]
16 Udumyan R, Montgomery S, Duberg AS, Fang F, Valdimarsdottir U, Ekbom A, Smedby KE, Fall K. Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients. Scand J Gastroenterol 2020;55:597-605. [PMID: 32412855 DOI: 10.1080/00365521.2020.1762919] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]